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Rapamycin (sirolimus) is a macrolide fungicide with
immunosuppressant properties that is used in human
islet transplantation. Little is known about the effects
of rapamycin on MIN-6 cells and islets. Rapamycin had a
dose-dependent, time-dependent, and glucose-indepen-
dent deleterious effect on MIN-6 cell viability. At day 1,
using the MTT method, 0.01 nmol/l rapamycin reduced
cell viability to 83  6% of control (P < 0.05). Using the
calcein AM method, at day 2, 10 nmol/l rapamycin
caused a reduction in cell viability to 73  5% of control
(P < 0.001). Furthermore, 10 and 100 nmol/l rapamycin
caused apoptosis in MIN-6 cells as assessed by the
transferase-mediated dUTP nick-end labeling assay.
Compared with control, there was a 3.1  0.6-fold
increase (P < 0.01) in apoptosis in MIN-6 cells treated
with 10 nmol/l rapamycin. A supra-therapeutic rapamy-
cin concentration of 100 nmol/l signiﬁcantly impaired
glucose- and carbachol-stimulated insulin secretion in
rat islets and had a deleterious effect on the viability of
rat and human islets, causing apoptosis of both - and
-cells. Diabetes 52:2731–2739, 2003
R
apamycin (sirolimus) is a macrolide fungicide
with potent antimicrobial, immunosuppressant,
and antitumor properties. As an immunosup-
pressant, it has a mechanism of action distinct
from that of cyclosporine, tacrolimus, corticosteroids, and
azathioprine. In humans, it has been used successfully as
an immunosuppressant in islet (1), combined kidney-
pancreas (2), renal (3), and liver (4) transplantation and as
rescue therapy in lung and heart transplantation (5).
Rapamycin has also found a role as a tool to suppress
neointimal hyperplasia of rapamycin-eluting coronary
stents in humans with coronary artery disease (6) and in
the porcine coronary model (7). Indeed, gene expression
proﬁling of human stent-induced neointima by cDNA array
analysis of microscopic specimens reveals upregulation of
FK506-binding protein 12 (FKBP12), the intracellular bind-
ing protein of rapamycin (8). Furthermore, CCI-779 (a
water-soluble ester analog of rapamycin) has signiﬁcant
activity against a wide range of in vitro human cancers. It
is currently undergoing clinical evaluation as an antitumor
agent (9).
The antiproliferative effects can be explained by under-
standing the intracellular mechanism of action of rapamy-
cin. Rapamycin binds intracellular FKBP12 to form a
complex, which binds to and inhibits the serine/threonine
kinase activity of the mammalian target of rapamycin
(mTOR) (10). Inhibition of mTOR blocks downstream
phosphorylation of several proteins. A reduction in the
kinase activity of p70
s6k results in reduced phosphoryla-
tion of the 40S ribosomal protein S6 (which is essential for
mRNA translation and hence protein synthesis) (11). Also,
there is increased binding of the dephosphorylated eukary-
otic initiation factor, 4E binding protein-1, or phosphory-
lated heat- and acid-stable protein, to the mRNA cap-
binding subunit of the eukaryotic initiation factor-4
complex, which inhibits its activity. This blocks the trans-
lation of mRNAs required for cyclin D1 synthesis, protein
synthesis, and cell cycle progression from G1 to S phase
(12). In addition, there is increased turnover of cyclin D1
at the protein and mRNA level. This effect, in addition to
the decreased translation of cyclin D1 (due to 4E binding
protein-1/eukaryotic initiation factor-4 inhibition) results
in a relative deﬁciency of cyclin D1, which is required for
G1-to-S phase transition (9).
Rapamycin causes cell death by apoptosis in BKS-2
lymphoma cell lines. Tacrolimus, which competes with
rapamycin for FKBP12 binding sites, inhibits rapamycin-
induced apoptosis, suggesting that, in this cell line, rapa-
mycin binding to FKBP12 is essential for programmed cell
death (13). In addition, rapamycin induces apoptosis in the
Rh1 and Rh30 rhabdomyosarcoma cell lines, and it is likely
that mTOR has a critical role in rapamycin-induced apo-
ptosis (14). Rapamycin enhances apoptosis and increases
sensitivity to cisplatin in the human promyelocytic leuke-
mia cell line HL-60 and the human ovarian cancer cell line
SKOV3 (15). Rapamycin can evoke apoptosis in human
dendritic cells, in a time- and dose-dependent manner (16).
The caspase inhibitor, ZVAD-fmk, only partially inhibits
rapamycin-induced apoptosis. Monocytes, macrophages
(either monocyte-derived or freshly isolated alveolar mac-
rophages), and myeloid cell lines are resistant to the
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DIABETES, VOL. 52, NOVEMBER 2003 2731apoptotic effect of rapamycin (16). In addition, interleu-
kin-7 prevents apoptosis of T-cell acute lymphoblastic
leukemia cells by downregulating the cyclin-dependent
kinase inhibitor p27
kip1 and upregulating bcl-2 expression.
The effect on p27
kip1 is inhibited by rapamycin, suggesting
that in its phosphorylated form, p27
kip1 acts as a tumor
suppressor gene (17). In addition, rapamycin inhibits
mitochondrial-based p70
s6k, which prevents phosphoryla-
tion of serine-136 on the proapoptotic BAD (the phosphor-
ylated form is inactive) and blocks cell survival induced by
IGF. Furthermore, IGF-1–induced phosphorylation of BAD
Ser-136 is abolished in p70
s6k-deﬁcient cells. This suggests
that p70
s6k, by phosphorylating and hence inactivating
BAD, is crucial to continued cell survival (18). Although
rapamycin inhibition of mTOR and subsequent dephos-
phorylation of p70
s6k resulted in a signiﬁcant reduction in
proliferation of BxPC3 and Panc-1 human pancreatic
adenocarcinoma cell lines, rapamycin alone did not induce
apoptosis in this cell line (19). In summary, rapamycin has
been shown to induce apoptosis in some cell lines but not
others.
Brittle type 1 diabetes is increasingly being treated by
human islet transplantation. In the Edmonton study (1),
the immunosuppressant regime included rapamycin, low-
dose tacrolimus, and daclizumab (a monoclonal antibody
against interleukin-2 receptor) but not corticosteroids or
cyclosporine. This regime was chosen because it is
thought that these drugs, including rapamycin, have little
net effect on -cell function and peripheral sensitivity to
insulin, which is an essential requirement for diabetic
patients receiving human islet transplants.
In the Edmonton study, blood rapamycin levels were
monitored to maintain them in the range of 12–15 ng/ml for
the ﬁrst 3 months and in the range of 7 to 10 ng/ml (or
7.66–10.9 nmol/l) thereafter. Another study (20) describes
a putative rapamycin therapeutic window in a renal trans-
plant regime that includes cyclosporine as 5–15 ng/ml (or
5.47–16.4 nmol/l).
The Edmonton study was not designed to assess the
effect of rapamycin on islet function. A previous study (21)
demonstrated that rapamycin, with or without cyclospor-
ine, is not associated with adverse impact on islet function
or glucose metabolism in the canine model of pancreatic
transplantation. Another study (22) demonstrated that
rapamycin induces primary nonfunction of islet xenografts
in a dose-dependent manner, suggesting that rapamycin
may be diabetogenic. Yet another study (23) demonstrated
that rapamycin reduces insulin secretion of HIT-T15 cells
after 48 h of culture, but rapamycin had no effect on
insulin secretion of Wistar rat islets after 24 h of culture.
The effect of rapamycin on the MIN-6 cells and islets is not
clear. Thus, the aim of our study was to address whether
rapamycin has any effect on MIN-6 cells and rat and human
islets in vitro.
RESEARCH DESIGN AND METHODS
MIN-6 cell culture. MIN-6 insulinoma cells were cultured in T175 cm ﬂasks
in 25-mmol/l glucose Dulbecco’s modiﬁed Eagle’s medium (DMEM), supple-
mented with 15% fetal bovine serum, 100 units/ml penicillin, 100 g/ml
streptomycin, and 2 mmol/l L-glutamine at 37°C under conditions of 95% air
and 5% CO2. The medium was changed every 3 or 4 days. Cells were
trypsinized weekly and passages 35–50 were used exclusively.
Isolation of pancreatic islets. The Children’s Hospital of Philadelphia
guidelines for the use and care of laboratory animals were followed. Male
Sprague-Dawley rats (Charles River Laboratories, Boston, MA) were injected
with nembutal (0.05 mg/g rat). After the rats were anesthetized, the bile duct
was cannulated, and the pancreas was inﬂated with 20 ml of Hanks’
balanced buffer. The inﬂated pancreas was removed and cleaned of its lymph
nodes, fat, blood vessels, and bile duct. Tissue was digested with collagenase
P (Roche Molecular Biochemicals) as previously described (24,25) and
puriﬁed on a discontinuous Ficoll gradient. Isolated islets were washed and
cultured in complete CMRL-1066 (supplemented with 10% fetal bovine serum,
2 mmol/l L-glutamine, 100 units/ml penicillin, and 100 g/ml streptomycin)
culture medium at 37°C (95% air and 5% CO2).
MIN-6 cell viability determination.
MTT. The MTT assay is an indirect measure of cell viability. The assay is
based on the ability of viable cells to reduce MTT (C,N-diphenyl-N4-5-
dimethyl thiazol-2-yl tetrazolium bromide) to insoluble colored formazan
crystals. MIN-6 cells (1.6  10
6) from one T175 ﬂask were plated in one 24-well
plate in 25-mmol/l glucose DMEM for 3–4 days. Thereafter, the medium was
removed and replaced with different glucose concentrations and different
rapamycin concentrations in DMEM for either 1, 2, or 4 days. After culture
with or without rapamycin, cells were washed twice with 1 ml Krebs-HEPES
buffer (115 mmol/l NaCl, 24 mmol/l NaHCO3, 5 mmol/l KCl, 1 mmol/l MgCl2,
2.5 mmol/l CaCl2, and 25 mmol/l HEPES, pH 7.4, and 1% BSA) with no glucose
and incubated in 1 ml Krebs-HEPES buffer (0 mmol/l glucose) with 0.5 mg/ml
MTT for 60 min at 37°C. The supernatant was discarded, and cells in each well
were lysed with 500 l of 2-propanol and incubated for 60 min at room
temperature. The optical density of the resultant colored 2-propanol was
measured at 560 nm on a MicroKinetics plate reader.
Fluorescent live/dead cell assay. A two-color ﬂuorescence cell viability
assay was used based on the ability of calcein AM to be retained within live
cells, inducing an intense uniform green ﬂuorescence and ethidium ho-
modimer (EthD-1) to bind the nuclei of damaged cells, thus producing a bright
red ﬂuorescence in dead cells. MIN-6 cells (1.6  10
6) from one T175 ﬂask
were plated in one 24-well plate in 15-mmol/l glucose DMEM for 3–4 days.
Thereafter, the medium was removed and replaced with different rapamycin
concentrations in 15-mmol/l glucose DMEM for either 2 or 4 days. After
culture with or without rapamycin, cells were washed twice with 0.5 ml sterile
PBS. The wash solution was then centrifuged, the supernatant removed, and
the pellet resuspended in 200 l PBS containing 2 mol/l calcein AM and 4
mol/l EthD-1. This solution was then returned to the appropriate well of the
24-well plate and incubated at room temperature for 45 min in darkness. The
green ﬂuorescence of the live cells was measured by the Wallac 1420
Multilabel Counter (PerkinElmer Life Sciences, Gaithersburg, MD). Excitation
was at 488 nm, and live cells were detected at a wavelength of 510 nm with a
bandpass ﬁlter. Images of the stained cells were captured by digital ﬂuores-
cence microscopy using the SimplePCI software (Compix Imaging Systems,
Cranberry, PA).
Cell viability in human islets. Human islets were obtained, with the
approval of the local ethics committee, from the Islet Isolation Core of the
Juvenile Diabetes Foundation International–-Penn Islet Transplantation Cen-
ter. Consent was obtained in accordance with accepted guidelines. Donor
details are described in Table 1. Purity was assessed by staining the prepara-
tion with dithizone and calculating the percentage of all tissue that stained
positive for insulin. Human islets were cultured in CMRL (supplemented with
10% fetal bovine serum, 2 mmol/l L-glutamine, and 100 units/ml penicillin) at
37°C under conditions of 95% air and 5% CO2 in a T75 ﬂask. All human islets
were removed from the ﬂask, washed, and resuspended in 12 ml CMRL. A
volume of islet suspension was added to each well of a 6-well plate. Either
vehicle control (0.1% ethanol) or rapamycin was added to each well. After 4
days culture, 0.2 ml of supernatant was removed from each well and 0.2 ml of
Krebs-HEPES buffer (0 mmol/l glucose) with 0.5 mg/ml MTT was added and
incubated for 120 min at 37°C. Thereafter, all well contents were removed,
spun, and the supernatant was removed. The islets were then washed with 1
ml Krebs-HEPES buffer. The supernatant was again discarded and 300 lo f
2-propanol was added and incubated for 60 min at room temperature. After
further centrifugation, 200 l of supernatant was removed for MTT analysis.
The optical density of the resultant colored 2-propanol was measured at 560
nm on a MicroKinetics plate reader.
TABLE 1
Characteristics of organ donors and human islet preparations
Islet preparation Age (years) Sex (M or F) Purity (%)
T71 46 M 90
T72 33 F 90
T75 17 F 60
T103 58 F 40
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dishes, containing 10 ml of supplemented CMRL-1066 and 1, 10, or 100 nmol/l
rapamycin or the vehicle control (0.1% ethanol). After 4 days culture, islets
were removed and washed twice in RPMI medium. Within each dish, rat islets
were divided into three groups depending on their size: small, medium, or
large. Five rat islets per well were counted into a 6-well plate, picked
sequentially, starting from the group of largest islets to the group of smallest
islets and then back to the group of largest islets and incubated in 1.5 ml of
either a low-glucose RPMI solution (3 mmol/l glucose) or a high-glucose RPMI
solution (20 mmol/l glucose) with 1 mmol/l carbachol at 37°C for 2 h. After
incubation, the supernatant was removed and analyzed for its insulin content
by radioimmunoassay (Penn Diabetes Center RIA Core).
Cell viability in rat islets. Propidium iodide (PI) is a highly polar dye, which
penetrates cells with damaged membranes and stains the nuclei red. Fifty rat
islets were cultured in 3 ml of supplemented CMRL-1066 and either 10 or 100
nmol/l rapamycin or the vehicle control (0.1% ethanol). After 4 days culture,
the PI solution was added to each well (ﬁnal concentration, 15 g/ml) and
incubated for 45 min in the dark at room temperature. Islets were then
removed, centrifuged, and the supernatant was removed and discarded. The
islets were resuspended in 60 l Krebs-HEPES buffer and transferred to a
384-well plate. The intensity of PI ﬂuorescence was measured by a Wallac 1420
Multilabel Counter (PerkinElmer Life Sciences, Gaithersburg, MD), with
excitation at 485 nm and emission at 630 nm. Fluorescent images were
captured by confocal ﬂuorescence microscopy at a pixel size of 0.546 m and
20 magniﬁcation with excitation at 488 nm and emission at 610 nm (Penn
Diabetes Center Biomedical Imaging Core). For each well, a minimum of 10
random size–matched islets were acquired under bright and ﬂuorescence
microscopy.
Identiﬁcation of apoptosis by transferase-mediated dUTP nick-end
labeling assay. An in situ Cell Death Detection kit (Boehringer Mannheim,
Indianapolis, IN) was used to detect apoptotic cells. In this method, terminal
deoxynucleotidyl transferase was used to catalyze the polymerization of
ﬂuorescein-labeled nucleotides to free 3-OH termini of DNA strand breaks.
After 19 h culture DMEM with vehicle control (0.1% ethanol), 10 or 100 nmol/l
rapamycin, MIN-6 cells were trypsinized and washed twice with cold PBS with
1% BSA. Cells were then ﬁxed with 200 l 2% paraformaldehyde and incubated
for 60 min at room temperature. After rinsing with PBS, cells were resus-
pended with 250 l of permeabilization solution (0.1% Triton X-100 in 0.1%
sodium citrate) and incubated for 30 min at room temperature. Then, 50 lo f
transferase-mediated dUTP nick-end labeling (TUNEL) reaction mixture was
added to samples and positive controls (50 l of label solution only was added
to negative controls), and cells were incubated at 37°C for 1 h. Apoptotic cells
were identiﬁed by ﬂuorescein isothiocyanate staining, and analyzed by ﬂow
cytometry. A Coulter EPICS Elite Flow cytometer (Beckman-Coulter, Hialeah,
FL) equipped with a 5-watt argon laser operated at 488 nm and 260 milliwatts
output was used for all studies. Monomeric forms of the MIN-6 cells were
electronically gated based on forward and side scatter measurements to
exclude cell aggregates from evaluation. Fluorescence signals were collected
with a photomultiplier tube conﬁgured with 550 nm dichroic and 525 nm
bandpass ﬁlters. Ten thousand events were collected into a four-decalog
single-parameter histogram for each sample. Percentage of positive cells were
determined based on the evaluation of cells treated with TUNEL reagents
lacking terminal deoxynucleotidyl transferase using a cursor setting that
yielded 2% positive cells.
Islet-cell apoptosis identiﬁed by electron microscopy. Rat islets were
cultured in complete CMRL-1066 in 6-cm dishes with vehicle or with rapamy-
FIG. 1. Dose-dependent effect of rapamycin on MIN-6 cell viability
measured by MTT metabolism. MIN-6 cells were plated in 24-well
plates and cultured for 3–4 days in 25-mmol/l glucose (G25) DMEM
(15% fetal bovine serum). Supernatant was removed, and cells were
further cultured with different concentrations of rapamycin or vehicle
control (0.1% ethanol) in G25 DMEM (15% fetal bovine serum) for 1
day (A), 2 days (B), or 4 days (C). Cell viability was measured by MTT
metabolism as described in RESEARCH DESIGN AND METHODS. Data are mean
(% of control mean)  SE of three experiments performed in quadru-
plicate (n  12). *P < 0.05, **P < 0.01, ***P < 0.001.
FIG. 2. Glucose-dependency of rapamycin effect on MIN-6 cell viability
measured by MTT metabolism. MIN-6 cells were plated in 24-well
plates and cultured for 3–4 days in 25-mmol/l glucose (G25) DMEM
(15% fetal bovine serum). Supernatant was removed, and cells were
further cultured with different concentrations of rapamycin or vehicle
control (0.1% ethanol) each in 3-mmol/l glucose (G3, s), 15-mmol/l
glucose (G15, u), and 25-mmol/l glucose (G25, f) DMEM (15% fetal
bovine serum) for 4 days. Cell viability was measured by MTT metab-
olism as described in RESEARCH DESIGN AND METHODS. Data are mean
(normalized to control mean in the absence of rapamycin)  SE of
three experiments from 8 to 12 observations. In the absence of
rapamycin, the absorbance for each condition was 0.236  0.40 (G3),
0.354  0.051 (G15), and 0.535  0.018 AU (G25). *P < 0.05.
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prewarmed serum-free medium and ﬁxed with 2.5% glutaraldehyde and 2%
paraformaldehyde in sodium cacodylate buffer for 4 h. The islets were
collected from the dish to make a pellet. After washing, osmication, and
dehydration with ethanol and propylene oxide, the pellets were embedded in
EM-Bed 812 and polymerized at 70°C for 48 h. Semithin sections (1 m) were
stained with Toluidine blue to screen general cell morphology. Ultrathin
sections (80 nm) were cut with a diamond knife, stained with uranyl acetate
and lead citrate, and examined with a JEOL-1010 transmission electron
microscope operated at the accelerated voltage of 80 kv.
Statistical analysis and data presentation. Data are presented as mean 
SE. Statistical signiﬁcance of differences between groups was analyzed by
one-way ANOVA and Newman-Keuls multiple comparison tests. The molecu-
lar weight of rapamycin is 914.2, thus a rapamycin concentration of 10 ng/ml
is actually 9.142 nmol/l. The rapamycin stock solutions used in this study were
made up to give 0.01, 0.1, 1, 10, and 100 ng/ml. However, to ease comparisons
with the units used in clinical therapeutic drug monitoring, the rapamycin
concentration data in the graphs are labeled as 0.01, 0.1, 1, 10, and 100 nmol/l.
RESULTS
Dose-dependent effect and time-course of rapamycin
on MIN-6 cell viability using MTT. To determine
whether rapamycin has a deleterious effect on MIN-6 cells,
MIN-6 cells were incubated with rapamycin concentra-
tions of 0 (vehicle control), 0.01, 0.1, 1, 10, and 100 nmol/l
in DMEM for 1, 2, or 4 days and then evaluated for cell
viability using the MTT method. As early as day 1 (Fig. 1A),
rapamycin started to reduce MIN-6 cell viability in a
dose-dependent manner. At day 1, the threshold concen-
tration causing decreased MIN-6 cell viability was 0.01
FIG. 3. Dose-dependent effect of rapamycin on MIN-6 cell viability measured by calcein ﬂuorescence. MIN-6 cells were plated in 24-well plates
and cultured for 3–4 days in 15-mmol/l glucose (G15) DMEM (15% fetal bovine serum). Supernatant was removed, and cells were further cultured
with different concentrations of rapamycin or vehicle control (0.1% ethanol) for 2 days (A) or 4 days (B). Cell viability was quantitated by calcein
ﬂuorescence as described in RESEARCH DESIGN AND METHODS. Data are mean ﬂuorescence (normalized to control mean)  SE of three experiments
performed in quadruplicate (n  12). Fluorescent images are of MIN-6 cells cultured with 0.1% ethanol (C) or 100 nmol/l rapamycin (D) for 4
days, then stained with calcein AM and EthD-1. ***P < 0.001.
FIG. 4. Effect of rapamycin on rat islet insulin secretion after 4 days of
culture. Rat islets were cultured with either 1, 10, or 100 nmol/l
rapamycin or vehicle control (0.1% ethanol) in supplemented CMRL
for 4 days. Islets were washed and then incubated for 2 h with 3 mmol/l
glucose (G3) or 20 mmol/l glucose and 1 mmol/l carbachol (G20/CCH).
Samples were then taken for insulin radioimmunoassay. Data are mean
insulin secretion (U  islet
1  2h
1)  SE in four experiments from 8
to 12 observations. **P < 0.01.
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maximal effect was at 10 nmol/l rapamycin (63  5% of
control, P  0.001), and half inhibitory concentration
(IC50) was 0.02 nmol/l rapamycin. At day 2 (Fig. 1B), the
threshold concentration was 0.01 nmol/l rapamycin (68 
6% of control, P  0.001), the maximal effect was at 10
nmol/l rapamycin (52  2% of control, P  0.001), and IC50
was 0.01 nmol/l rapamycin. At day 4 (Fig. 1C), the thresh-
old concentration was again 0.01 nmol/l rapamycin (77 
4% of control, P  0.001). The maximal effect was not
reached at day 4 and hence the IC50 could not be calcu-
lated. The threshold concentration at days 1, 2, and 4 was
the same (0.01 nmol/l rapamycin), although the level of
signiﬁcance increased from day 1 to days 2 and 4. The IC50
fell from 0.02 nmol/l rapamycin at day 1 to 0.01 nmol/l
rapamycin at day 2. These results suggest that rapamycin
has a dose-dependent deleterious effect on MIN-6 cell
viability, evident at 1 day by using the MTT method.
Glucose-dependency of rapamycin effect on MIN-6
cell viability. These experiments were designed to assess
whether the rapamycin effect on MIN-6 cell viability, as
measured by the MTT method, was glucose-dependent
after 4 days culture (Fig. 2). MIN-6 cells cultured in 3 or 15
mmol/l glucose in DMEM had a threshold concentration of
0.1 nmol/l rapamycin (78  5% of control, P  0.05, and
76  1% of control, P  0.05, respectively). MIN-6 cells
cultured in 25-mmol/l glucose DMEM had a threshold
concentration of 0.01 nmol/l rapamycin (77  4% of
control, P  0.05). The maximal effect was not reached for
3 or 25 mmol/l glucose, but MIN-6 cells cultured in 15
mmol/l glucose had a maximal effect at 10 nmol/l rapamy-
cin (49  5% of control, P  0.05) and an IC50 of 0.09
nmol/l rapamycin. At each rapamycin concentration (0.01
up to 100 nmol/l) there was no signiﬁcant difference
between the cell viability of MIN-6 cells cultured for 4 days
in 3, 15, or 25 mmol/l glucose. These results suggest that
the dose-dependent effect of rapamycin on MIN-6 cell
viability is glucose independent.
Dose-dependent effect and time-course of rapamycin
on MIN-6 cell viability using calcein AM. The afore-
mentioned MTT assay is an indirect measure of cell
viability—it actually measures formazan, which is a purple
substance formed by the oxidation of yellow MTT by the
action of mitochondrial succinate dehydrogenase. Hence,
the more mitochondrial succinate dehydrogenase present,
the greater the purple intensity of the sample. However, it
is possible that the overall activity of succinate dehydro-
genase is not only related to the number of viable cells
present. It is difﬁcult to exclude an intracellular metabolic
effect of rapamycin, which may be having an inhibitory
effect on succinate dehydrogenase. For this reason, we
attempted to demonstrate reduced MIN-6 cell viability by a
different method, a two-color ﬂuorescence cell viability
assay. This assay is based on the ability of calcein AM to be
retained within live cells, inducing an intense uniform
green ﬂuorescence and EthD-1 to bind the nuclei of
damaged cells. Thus the more green ﬂuorescence present,
the more live cells present in the sample. At day 2 (Fig.
3A), the threshold effect was at 10 nmol/l rapamycin (73 
5% of control, P  0.001), with no maximal effect achieved.
At day 4 (Fig. 3B), the threshold effect was at 0.1 nmol/l
rapamycin (54  5% of control, P  0.001), with a maximal
effect at 10 nmol/l rapamycin (40  4% of control, P 
0.001) and an IC50 of 0.01 nmol/l rapamycin. The ﬂuores-
FIG. 5. Effect of rapamycin on rat islet cell viability. A: Rat islets
were cultured with either 1, 10, or 100 nmol/l rapamycin or vehicle
control (0.1% ethanol) in supplemented CMRL for 4 days. Islets
were then stained with PI and the ﬂuorescence intensity measured
as described in RESEARCH DESIGN AND METHODS. Data are mean
ﬂuorescence (normalized to control mean)  SE in six experi-
ments. Rat islets were cultured with 0.1% ethanol (B)o r1 0 0
nmol/l rapamycin (C) for 4 days and then stained with PI. A bright
ﬁeld image was ﬁrst acquired followed by a confocal image to
detect PI ﬂuorescence and overlaid. **P < 0.01.
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red ﬂuorescence in those cells treated with rapamycin
(Fig. 3D) compared with control (Fig. 3C). These results
conﬁrm the previous ﬁndings, using the MTT method, that
rapamycin does indeed have a dose-dependent deleterious
effect on MIN-6 cell viability.
Effect of rapamycin on rat islet insulin secretion. To
determine whether rapamycin has any effect on glucose-
stimulated insulin secretion of rat islets, they were cul-
tured with vehicle control (0.1% ethanol) or different
concentrations of rapamycin for 4 days, and thereafter a
2-h static incubation test was performed on each group of
islets. The rat islets cultured in vehicle control (0.1%
ethanol) had a fourfold increase in insulin secretion in
response to 20 mmol/l glucose and 1 mmol/l carbachol
compared with 3 mmol/l glucose control (Fig. 4). At
rapamycin concentrations of 1 and 10 nmol/l, there was a
reduction in glucose-induced insulin secretion, which was
not statistically signiﬁcant. At a supra-therapeutic rapamy-
cin concentration of 100 nmol/l, however, there was a 54%
reduction (from 198  25 to 90  8 U  islet
1  2h
1)i n
glucose and carbachol-induced insulin secretion (P 
0.01). Basal insulin secretion (3 mmol/l glucose) was not
affected by rapamycin at any concentration tested. These
results suggest that a supra-therapeutic rapamycin con-
centration of 100 nmol/l signiﬁcantly impairs glucose-
induced insulin secretion.
Effect of rapamycin on rat and human islet cell
viability. To determine whether rapamycin has any effect
on human and rat islet cell viability, islets were cultured
with vehicle control (0.1% ethanol) or rapamycin for 4
days, and then cell viability was measured by different
methods. After 4 days culture in different rapamycin
concentrations, rat islets were stained with propidium
iodide to quantify rat islet cell death (Fig. 5A). At 1 and 10
nmol/l rapamycin, there was a small, insigniﬁcant increase
in PI ﬂuorescence, but at a supra-therapeutic rapamycin
concentration of 100 nmol/l, there was a 5.3-fold increase
in PI ﬂuorescence (P  0.01). The confocal images of rat
islets demonstrate increased PI ﬂuorescence from the islet
cultured with rapamycin (Fig. 5C) compared with control
(Fig. 5B). Human islets were cultured for 4 days with a
supra-therapeutic rapamycin concentration of 100 nmol/l
or control, and then human islet cell viability measured
using the MTT method (Fig. 6). There was a 55% reduction
in MTT metabolism compared with control islets (P 
0.001). These results suggest that a supra-therapeutic
rapamycin concentration of 100 nmol/l has a deleterious
effect on rat and human islets.
Rapamycin induces apoptosis in MIN-6 cells. To assess
whether rapamycin induces apoptosis, MIN-6 cells were
treated with either vehicle control (0.1% ethanol) or 10 or
100 nmol/l rapamycin for 19 h, and then the degree of
apoptosis was measured by the TUNEL assay (Fig. 7).
Compared with control, there was a 3.1  0.6 fold increase
(P  0.01) in apoptosis in the MIN-6 cells treated with 10
nmol/l rapamycin and a 3.4  0.4 fold increase (P  0.01)
in apoptosis in the MIN-6 cells treated with a supra-
therapeutic rapamycin concentration of 100 nmol/l. These
results suggest that 10 and 100 nmol/l (a supra-therapeutic
concentration) rapamycin induces apoptosis in MIN-6
cells.
Rapamycin induces apoptosis in rat islets. Rapamycin
causes cell death of rat islet cells as assessed by electron
microscopy. Rapamycin treatment of rat islets resulted in
numerous apoptotic -cells (Fig. 8B) as well as 	-cells
(Fig. 8C). -Cells were identiﬁed by their speciﬁc square
shape granules, and 	-cells were recognized by their round
dark granules by electron microscopy. Vehicle-treated
islet cells had a normal ultrastructure (Fig. 8A). In con-
trast, rapamycin-treated islet cells showed typical apopto-
tic morphologic changes, including nuclei condensation,
granule dilution, clumped and condensed mitochondria,
nuclear envelopes with irregular dilation, as well as some
typical apoptotic bodies (Fig. 8D).
DISCUSSION
We have demonstrated for the ﬁrst time, by several
methods, that a therapeutic concentration of rapamycin
causes cell death of the transformed MIN-6 cell line and
that a supra-therapeutic rapamycin concentration has a
deleterious effect on primary islet cells. In MIN-6 cells, this
effect starts to occur as early as day 1 with a very low
FIG. 6. Effect of rapamycin on human islet cell viability after 4 days of
culture. Human islets were cultured with either rapamycin or vehicle
control (0.1% ethanol) in supplemented CMRL for 4 days. Cell viability
was measured by MTT metabolism as described in RESEARCH DESIGN AND
METHODS. Data are mean (normalized to control mean)  SE of four
experiments with 11 observations. ***P < 0.001.
FIG. 7. Effect of rapamycin on MIN-6 cell apoptosis. MIN-6 cells were
cultured with either 10 or 100 nmol/l rapamycin or vehicle control
(0.1% ethanol) in 5-mmol/l glucose DMEM for 19 h, then apoptotic cells
were measured by ﬂow cytometric TUNEL assay as described in
RESEARCH DESIGN AND METHODS. Data are mean (normalized to control
mean)  SE of four experiments from seven to eight observations.
**P < 0.01.
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MTT method. Why the MTT method appears to be more
sensitive than the calcein method (at day 2, the threshold
concentration is 10 nmol/l) is not easily explained. This
may reﬂect the fact that calcein staining is indicative of
cell death only, whereas MTT measurement reﬂects two
cellular processes, namely cell viability and mitochondrial
metabolism. As such, rapamycin may not only reduce cell
viability but also have an additional inhibitory effect on
mitochondrial metabolism. The effect of rapamycin does
not seem to be modulated by glucose concentration in the
medium.
To conﬁrm the ﬁndings observed in the clonal insulin-
producing MIN-6 cells, the effect of rapamycin was also
studied in rat and human islets. The rat islet PI ﬂuores-
cence experiment was designed to assess whether rapa-
mycin causes rat islet cell damage. However, there was
only a signiﬁcant effect at a supra-therapeutic rapamycin
concentration of 100 nmol/l. We also showed that this
concentration of rapamycin reduces human islet cell via-
bility, by the MTT method. These results conﬁrm that
rapamycin toxicity at therapeutic concentrations is limited
to the MIN-6 cell line, and only at supra-therapeutic
concentrations does rapamycin have a deleterious effect
FIG. 8. Effect of rapamycin on islet-cell apoptosis. Rat islets were cultured in CMRL-1066 (10% fetal bovine serum). Islets were treated with
vehicle (A) or with rapamycin 100 ng/ml (B, C, and D) for 4 days. Cell apoptosis was assessed by electron microscopy as described in RESEARCH
DESIGN AND METHODS. Apoptotic cells (-cells, B, and -cells, C) in islets were detected by nuclear condensation (a), nuclear envelope irregular
dilation (b), granule dilution (c), clumped and condensed mitochondria (d), and apoptotic bodies (solid arrows, D). Data are representative of
two independent experiments.
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data demonstrate that rapamycin-induced MIN-6 cell death
occurs by apoptosis.
In addition to causing MIN-6 cell apoptosis, rapamycin
also impairs insulin secretion in the static-incubation
insulin-secretion test. In this study, the observed reduction
in insulin secretion may be attributed in part to the
reduced rat islet cell viability and in part to an intracellular
signaling impairment, such as inhibition of mitochondrial
glucose oxidation as possibly demonstrated indirectly by
the effect of rapamycin on MTT metabolism.
The mechanisms of rapamycin-induced reduction of
insulin secretion and MIN-6 cell viability are currently not
completely understood. The apoptotic effects may involve
the inhibition of mTOR and its downstream effectors. This
may result in increased levels of phosphorylated proapop-
totic factors (and tumor suppressor genes) and/or reduced
levels of antiapoptotic factors. An alternative hypothesis
may be a disruption of normal translation of proteins,
which are essential for continued cell survival (the mTOR
cell-survival pathway) (18).
The successful normalization of glucose control in brit-
tle type 1 diabetic patients using the Edmonton Protocol
has provided a potential cure for this disease. However,
the long-term side effects of this protocol are still not
clear, such as whether the immunosuppressants used can
cause -cell toxicity. In the landmark Edmonton Study (1),
patients had trough blood rapamycin levels monitored to
maintain them in the range of 12–15 ng/ml for the ﬁrst 3
months after transplant and in the range of 7–10 ng/ml
thereafter. It is suggested by various authors that the
target therapeutic range for whole blood trough concen-
trations of rapamycin is 5–10 ng/ml (26) or 5–15 ng/ml (20)
with concomitant cyclosporine treatment. The rapamycin
concentrations required to cause in vitro MIN-6 cell death
and apoptosis are similar to the range of whole blood
trough rapamycin concentrations desired in patients re-
ceiving rapamycin as an immunosuppressant. The rapamy-
cin concentration required to evoke deleterious effects on
rat and human islets in our in vitro study is supra-
therapeutic; nonetheless, transplanted islets are also ex-
posed to higher whole blood peak rapamycin concentrations.
Furthermore, human islets transplanted into the portal
vein are exposed to higher peak rapamycin concentra-
tions, following gastrointestinal absorption of rapamycin,
than the concentrations present in the circulating periph-
eral whole blood. Indeed, peak rapamycin levels in portal
blood have been observed to be double the levels found
systemically (27).
A previous study (23) demonstrated that 10 and 100
nmol/l rapamycin had no effect on rat islet insulin secre-
tion after 24 h culture. We found that culturing rat islets
with a supra-therapeutic rapamycin concentration of 100
nmol/l for 4 days did indeed reduce insulin secretion. This
difference may be explained by the insufﬁcient duration of
exposure of rat islets to rapamycin in the previous study.
In summary, this is the ﬁrst report to demonstrate that
therapeutic concentrations of rapamycin can cause in
vitro MIN-6 cell apoptosis and that supra-therapeutic
concentrations of rapamycin in vitro can have a deleteri-
ous effect on rat and human islets and reduce rat islet
insulin secretion. More work needs to be done on rat and
human islets to establish whether therapeutic concentra-
tions of rapamycin have any effect on primary -cells and
whether there are any consequent clinical implications.
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